RNXT · RENOVORX INC
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
2570 West El Camino Real, Mountain View, CA, 94040, United States
Biotechnology
Healthcare
Market Cap
55.97M
52 Wk Range
$0.70 - $2.59
Previous Close
$1.16
Open
$1.18
Volume
815,158
Day Range
$1.04 - $1.20
Enterprise Value
48.82M
Cash
10.4M
Avg Qtr Burn
-2.539M
Insider Ownership
3.60%
Institutional Own.
20.54%
Qtr Updated
Sep 30th 2026